UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

  

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

 

For the month of August 2017

 

Commission File Number: 001-37643

 

KITOV PHARMACEUTICALS HOLDINGS LTD.

(Translation of registrant’s name into English)

 

One Azrieli Center, Round Tower, Tel Aviv 6701101, Israel

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. 

 

Form 20-F ☒    Form 40-F ☐

 

Indicate by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____ 

 

Indicate by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____ 

 

 

 

 

 

On August 16, 2017, Kitov Pharmaceuticals Holdings   Ltd. (the “Company” or the “Registrant”) issued a Press Release: “ Kitov Pharmaceuticals Provides Corporate Update and Reports First Half 2017 Financial Results .” A copy of this press release, together with the Company’s unaudited condensed consolidated interim financial statements as of June 30, 2017, and for the six months then ended, are furnished herewith as Exhibits 99.1 and 99.2, respectively.

 

This report on Form 6-K of the Registrant consists of the following documents, which are attached hereto:

 

Exhibits

 

99.1 Press Release
99.2 The Registrant’s unaudited condensed consolidated interim financial statements as of June 30, 2017, and for the six months then ended.

 

The information contained within this report on Form 6-K and all Exhibits attached hereto should be read in conjunction with (1) our Unaudited Condensed Consolidated Interim Financial Statements as of June 30, 2017, and for the six months then ended; and, (2) our audited consolidated financial statements for the year ended December 31, 2016, which appears in the Company’s Annual Report on Form 20-F filed with the Securities and Exchange Commission on May 1, 2017, as well as the other information contained in such Annual Report on Form 20-F and in our Registration Statements filed with the SEC.

 

The text which is found under the headings entitled “Financial Results for Six Months Ended June 30, 2017” and “Balance Sheet Highlights”, respectively, in Exhibit 99.1 attached hereto; and, the entire Exhibit 99.2 attached hereto, are all hereby incorporated by reference into each of the Registrant’s Registration Statements on Form F-3 filed with the Securities and Exchange Commission on December 12, 2016 (Registration file numbers 333-207117, 333-211477 and 333-215037), the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on May 20, 2016 (Registration file number 333-211478), and the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on June 6, 2017 (Registration file number 333-218538).

 

  2  

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. 

 

  KITOV PHARMACEUTICALS HOLDINGS LTD.
   
Date: August 16, 2017 By: /s/ Avraham Ben-Tzvi
    Avraham Ben-Tzvi
    Company Secretary

 

 

3

 

Kitov Pharma (NASDAQ:KTOV)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Kitov Pharma Charts.
Kitov Pharma (NASDAQ:KTOV)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Kitov Pharma Charts.